This article is more than 5 years old. Information may no longer be current.

Nicox finalizes acquisition of Aciex Therapeutics

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nicox has announced the completion of its acquisition of Aciex Therapeutics, according to a press release.

In July, Nicox signed an agreement to acquire outstanding equity in Aciex Therapeutics, including a $65 million upfront payment in newly issued Nicox shares and contingent value rights to shares that may increase the purchase total to a maximum of $120 million, according to previously issued press release from Nicox.

The acquisition will expand Nicox’s development pipeline to include Aciex’s AC-170 for allergic conjunctivitis, according to the July press release. AC-170 has completed two phase 3 safety and efficacy trials.

Nicox plans to seek a pre-New Drug Application (NDA) meeting before submitting an NDA for AC-170. The company is also developing the therapeutic candidate, AC-155, to treat postoperative inflammation and pain and is expected to begin a phase 2 trial next year, according to the previous press release.